Sahai Supreet K, Majic Tamara, Patel Jignesh, Nurok Michael, Moheet Asma M, Rosengart Axel J, Lahiri Shouri
Department of Neurology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center, Cedars-Sinai Heart Institute, Los Angeles, CA, USA.
Neurohospitalist. 2017 Jan;7(1):35-38. doi: 10.1177/1941874416648195. Epub 2016 May 11.
A neuron-specific enolase level greater than 33 ng/mL at days 1 to 3 or status myoclonus within 1 day are traditional indicators of poor neurological prognosis in survivors of cardiac arrest. We report the case of a 70-year-old man who received extracorporeal membrane oxygenation following cardiac arrest. Despite having both an elevated neuron-specific enolase concentration of 68 ng/mL and status myoclonus, he made an excellent neurological recovery. The value of traditional markers of poor prognosis such as elevated neuron-specific enolase or status myoclonus has not been systematically validated in patients treated with extracorporeal membrane oxygenation or therapeutic hypothermia. Straightforward application of practice guidelines in these cases may result in tragic outcomes. This case underscores the need for reliable prognostic markers that account for recent advances in cardiopulmonary and neurological therapies.
心脏骤停幸存者中,第1至3天神经元特异性烯醇化酶水平大于33 ng/mL或1天内出现肌阵挛状态是神经功能预后不良的传统指标。我们报告了一例70岁男性在心脏骤停后接受体外膜肺氧合治疗的病例。尽管他的神经元特异性烯醇化酶浓度升高至68 ng/mL且存在肌阵挛状态,但他的神经功能恢复良好。在接受体外膜肺氧合或治疗性低温治疗的患者中,神经元特异性烯醇化酶升高或肌阵挛状态等预后不良传统标志物的价值尚未得到系统验证。在这些病例中直接应用实践指南可能会导致悲剧性后果。该病例强调了需要有可靠的预后标志物,以考虑到心肺和神经治疗方面的最新进展。